Dexamethasone Plus Virtual Reality Exposure Therapy for PTSD
NCT01965366
Completed
Evidence from preliminary studies suggests that people with PTSD have heightened fear responses and that cortisol suppression reduces this heightened fear. Research has shown the drug dexamethasone (DEX), a cortisol suppressor, reduces the startle response in civilians with PTSD. This current research proposal represents a blinded, randomized, placebo-controlled efficacy study with the goal of determining whether a drug that suppresses the stress hormone cortisol will increase the efficacy of ex... Read More
Gender:
ALL
Ages:
Between 21 years and 65 years
Trial Updated:
07/10/2018
Locations: Emory University, Atlanta, Georgia
Conditions: PTSD
Register for Updates
Analgesia Duration of Dexamethasone, Buprenorphine, or Clonidine With Ropivacaine for Interscalene Nerve Block
NCT03117140
Completed
This is a prospective randomized controlled triple-masked study looking at the duration of nerve block analgesia when using the listed adjuvants (dexamethasone, buprenorphine and clonidine) plus ropivacaine versus plain ropivacaine alone.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/02/2018
Locations: University of Iowa Hospital and Clinics, Ambulatory Surgery Clinic, Iowa City, Iowa
Conditions: Anesthesia, Local
Register for Updates
A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM)
NCT02720510
Terminated
This was a multicenter, open-label, randomized phase II study which were to enroll 112 newly diagnosed symptomatic multiple myeloma patients in a 1:1 fashion. Patients were to enroll at approximately 20 centers in the United States. Patients were to undergo stem cell mobilization with plerixafor plus Granulocyte Colony Stimulating Factor (G-CSF), according to investigator discretion, after 4 cycles of induction therapy. Study treatment interruption for stem cell collection were not to exceed 30... Read More
Gender:
ALL
Ages:
Between 18 years and 74 years
Trial Updated:
06/26/2018
Locations: David Geffen School of Medicine at UCLA UCLA, Los Angeles, California +4 locations
Conditions: Multiple Myeloma
Register for Updates
A Safety Study of Intravenous Pro-Netupitant and Palonosetron Combination for the Prevention of Nausea and Vomiting
NCT02517021
Completed
NEPA-15-18 is a clinical study assessing safety of pro-netupitant and palonosetron, two antiemetic drugs, given with oral dexamethasone. The objective of the study is to evaluate if pro-netupitant and palonosetron are safe when administered to prevent nausea and vomiting after administration of repeated cycles of chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2018
Locations: Sarcoma Oncology Center, Santa Monica, California +73 locations
Conditions: Chemotherapy-Induced Nausea and Vomiting
Register for Updates
Dexamethasone in Reducing Oral Pain and Dry Mouth After Surgery in Patients With Oropharyngeal Cancer
NCT01748942
Completed
This randomized pilot clinical trial studies dexamethasone in reducing oral pain and dry mouth after surgery in patients with oropharyngeal cancer. Dexamethasone may help lower pain and dry mouth caused by surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/12/2018
Locations: OHSU Knight Cancer Institute, Portland, Oregon
Conditions: Dysphagia, Pain, Stage I Oropharyngeal Squamous Cell Carcinoma, Stage II Oropharyngeal Squamous Cell Carcinoma, Stage III Oropharyngeal Squamous Cell Carcinoma
Register for Updates
Chalazion Conservative Treatment Trial
NCT01230593
Completed
An eyelid stye, or chalazion, is the most common eyelid ailment, and is caused by the blockage of one of the oil secreting glands of the eyelid (meibomian glands). This leads to a typically painful, swollen, and red eyelid bump that lasts from days to weeks and months. The chalazion may cause tearing, pressure on the cornea, and irritation, all of which contribute to its morbidity. There are many anecdotal first line treatments for this condition, including warm compresses to the eyelid, topical... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/09/2018
Locations: Elmhurst Hospital Center, Elmhurst, New York +2 locations
Conditions: Chalazion Unspecified Eye, Unspecified Eyelid, Chalazion Left Eye, Unspecified Eyelid, Chalazion Right Eye, Unspecified Eyelid, Chalazion Both Eyes
Register for Updates
E7070, Idarubicin and Cytarabine in Relapsed AML and High-Risk Myelodysplastic Syndromes
NCT01692197
Completed
The goal of this clinical research study is to learn if E7070 in combination with idarubicin, cytarabine, and dexamethasone can help to control the disease in patients with either AML or high-risk MDS that has relapsed. The safety of the drug combination will also be studied.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/04/2018
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Leukemia
Register for Updates
Phase II Study of Dexamethasone, Thalidomide and Lenalidomide for Subjects With Relapsed or Refractory Multiple Myeloma
NCT00538824
Terminated
Study Objectives 1. To evaluate the efficacy of the combination of dexamethasone (Decadron®), thalidomide (Thalomid®), and lenalidomide (Revlimid®) as therapy for patients with relapsed or refractory multiple myeloma (MM) who have failed prior treatment with both lenalidomide and thalidomide when used as monotherapies. 2. To evaluate the safety of the combination of lenalidomide, dexamethasone, and thalidomide as a therapy for patients with relapsed or refractory multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/31/2018
Locations: Weill Medical College of Cornell University, New York, New York
Conditions: Multiple Myeloma
Register for Updates
Study of Pomalidomide, Dexamethasone, and Romidepsin for Rel/Ref Myeloma
NCT01979276
Terminated
This clinical trial is for subjects with multiple myeloma that has returned after treatment (relapsed) or did not respond to prior treatment (refractory). The study is in two parts, Phase I and Phase II. Phase I will determine the maximum tolerated dose of romidepsin in combination with pomalidomide and dexamethasone. The purpose of Phase II is to evaluate the effectiveness of combining romidepsin with pomalidomide and dexamethasone. The hypothesis is that overall response in a cohort of patient... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
05/31/2018
Locations: Weill Cornell Medical College, New York, New York
Conditions: Multiple Myeloma
Register for Updates
Optimal Injection Site for Serratus Anterior Plane Block in Reconstructive Breast Surgery
NCT03183596
Withdrawn
The novel introduction of various chest wall blocks such as the Pecs I and II/modified Pecs blocks as well as the Serratus Anterior Plane Block have extended the application of perioperative regional anesthesia to provide analgesia for breast surgery. However, to our knowledge, there are no large studies that truly delineate the optimal injection site for the Serratus Anterior Plane Block.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
05/29/2018
Locations: UAB Department of Anesthesiology and Perioperative Medicine, Birmingham, Alabama
Conditions: Pain, Postoperative
Register for Updates
Iontophoretic Delivery of EGP-437 in Patients Who Have Undergone Cataract Surgery
NCT03180255
Completed
Phase 2b trial evaluating the safety and efficacy of EGP-437, versus placebo using the EyeGate® II Drug Delivery System (EGDS) in patients having undergone cataract surgery with implantation of a monofocal posterior chamber intraocular lens (IOL).
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
05/17/2018
Locations: Site 901, Jacksonville, Florida
Conditions: Cataract, Anterior Chamber Inflammation, Pain, Postoperative
Register for Updates
Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
NCT01711528
Completed
This phase I trial studies the side effects and best dose of dinaciclib and bortezomib when given together with dexamethasone in treating patients with multiple myeloma that has returned after a period of improvement. Dinaciclib and bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from div... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/10/2018
Locations: Mayo Clinic in Arizona, Scottsdale, Arizona +5 locations
Conditions: Recurrent Plasma Cell Myeloma
Register for Updates